BHLHE40-AS1, which lies antisense to the BHLHE40 promoter, functions independently of BHLHE40 and has been shown to modulate IL-6/STAT3 signaling in early-stage breast cancer, contributing to an immunosuppressive TME that promotes tumor progression [41]. Here, IL6 is linked to breast carcinoma.